Radiation-induced inferior brachial plexopathy after stereotactic body radiotherapy: Pooled analyses of risks

Abstract

<h3>Introduction</h3><p>Radiation-induced brachial plexopathy (RIBP), resulting in symptomatic motor or sensory deficits of the upper extremity, is a risk after exposure of the brachial plexus to therapeutic doses of radiation. We sought to model dosimetric factors associated with risks of RIBP after stereotactic body radiotherapy (SBRT).</p><h3>Methods</h3><p>From a prior systematic review, 4 studies were identified that included individual patient data amenable to normal tissue complication probability (NTCP) modelling after SBRT for apical lung tumors. Two probit NTCP models were derived: one from 4 studies (including 221 patients with 229 targets and 18 events); and another from 3 studies (including 185 patients with 192 targets and 11 events) that similarly contoured the brachial plexus.</p><h3>Results</h3><p>NTCP models suggest ≈10% risks associated with brachial plexus maximum dose (D_max) of ∼32–34 Gy in 3 fractions and ∼40–43 Gy in 5 fractions. RIBP risks increase with increasing brachial plexus D_max. Compared to previously published data from conventionally-fractionated or moderately-hypofractionated radiotherapy for breast, lung and head and neck cancers (which tend to utilize radiation fields that circumferentially irradiate the brachial plexus), SBRT (characterized by steep dose gradients outside of the target volume) exhibits a much less steep dose–response with brachial plexus D_max > 90–100 Gy in 2-Gy equivalents.</p><h3>Conclusions</h3><p>A dose–response for risk of RIBP after SBRT is observed relative to brachial plexus D_max. Comparisons to data from less conformal radiotherapy suggests potential dose-volume dependences of RIBP risks, though published data were not amenable to NTCP modelling of dose-volume measures associated with RIBP after SBRT.</p>